TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›SXTP›Financials
Annual statements · SEC XBRL · FY2022 – FY2025

60 DEGREES PHARMACEUTICALS, INC. (SXTP) financials

Income statement

60 DEGREES PHARMACEUTICALS, INC. (SXTP) income statement, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Revenue$223K$254K$608K$1.01M
Revenue growth—13.6%139.6%65.5%
Gross profit-$209K-$221K$223K$224K
Gross margin-93.7%-87.1%36.7%22.3%
Operating income-$1.75M-$5.15M-$9.72M-$7.76M
Operating margin-784.2%-2032.8%-1599.0%-771.6%
Net income-$6.18M-$3.77M-$7.95M-$7.37M
Net margin-2769.5%-1485.1%-1308.0%-732.5%
EPS (diluted)-$2.61-$59.18-$74.17-$11.73

Cash flow

60 DEGREES PHARMACEUTICALS, INC. (SXTP) cash flow, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Operating cash flow-$1.01M-$4.54M-$5.65M-$6.85M
Capital expenditures—$57.6K$104K$140K
Free cash flow—-$4.60M-$5.75M-$6.99M

Balance sheet

60 DEGREES PHARMACEUTICALS, INC. (SXTP) balance sheet, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Cash & equivalents$265K$2.14M$1.66M$1.51M
Total assets$1.30M$7.78M$5.76M$5.37M
Total liabilities$25.4M$2.99M$1.80M$1.99M
Long-term debt—$150K$147K$144K
Shareholders' equity-$23.6M$4.87M$4.04M$3.46M
Retained earnings-$28.8M-$32.6M-$40.5M-$47.9M
Shares (wtd avg diluted)2.37M66.3B114K670K

Every figure is extracted from 60 DEGREES PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is 60 DEGREES PHARMACEUTICALS, INC.'s annual revenue?
60 DEGREES PHARMACEUTICALS, INC. (SXTP) reported $1.01M of revenue for fiscal year 2025 — up 65.5% from $608K in FY2024, per its annual report filed with the SEC.
Is 60 DEGREES PHARMACEUTICALS, INC. profitable?
Not in FY2025 — SXTP reported a net loss of $7.37M, per SEC filings.
What is 60 DEGREES PHARMACEUTICALS, INC.'s free cash flow?
-$6.99M in FY2025 (operating cash flow -$6.85M minus $140K of capital expenditures), from the SEC cash-flow statement.
Does SXTP pay a dividend?
60 DEGREES PHARMACEUTICALS, INC. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full SXTP analysis — verdict, score & filings →Is SXTP a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.